Scholar Rock Holding (SRRK) Depreciation & Amortization (CF) (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Depreciation & Amortization (CF) came in at $335000.0 in Q1 2026, down 14.76% year-on-year from $393000.0 in Q1 2025, and down 21.18% quarter-over-quarter from $425000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $335000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 14.76% year-over-year to $335000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 5.72% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 12.74% from the prior year.
- Depreciation & Amortization (CF) declined to $335000.0 in Q1 2026 per SRRK's latest filing, from $425000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $763000.0 in Q4 2022 and bottomed at $335000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $598000.0 (2024), against an average of $572882.4.
- Across the five-year window, Depreciation & Amortization (CF) rose 26.95% in 2022 and plunged 46.73% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $763000.0 in 2022, then decreased by 11.93% to $672000.0 in 2023, then plunged by 46.73% to $358000.0 in 2024, then climbed by 18.72% to $425000.0 in 2025, then decreased by 21.18% to $335000.0 in 2026.
- Per Business Quant, the three latest SRRK Depreciation & Amortization (CF) figures stand at $335000.0 (Q1 2026), $425000.0 (Q4 2025), and $423000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 335,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,000.00 |
| Mar 31, 2026 | 335,000.00 |
| Dec 31, 2025 | 425,000.00 |
| Dec 31, 2025 | 425,000.00 |
| Sep 30, 2025 | 423,000.00 |
| Sep 30, 2025 | 423,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Dec 31, 2024 | 358,000.00 |
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 672,000.00 |
| Dec 31, 2023 | 672,000.00 |